natgillin/translations-raw huggingface dataset:
In an exploratory analysis in this subgroup, a response was noted in 18% (95% CI 12% - 26%) of patients (n=26) on rucaparib compared to 8% (95% CI 3% - 17%) of patients (n=5) on placebo (2-sided p-value = 0.0069), including 10 patients (7%) in the rucaparib group who achieved a complete remission. 
V eksplorativni analizi te podskupine so odziv ugotovili pri 18 % (95-odstotni IZ 12 % - 26 %) bolnic (n = 26), ki so prejemale rukaparib, v primerjavi z 8 % (95-odstotni IZ 3 % - 17 %) bolnic (n = 5), ki so prejemale placebo (dvostranska p-vrednost = 0,0069), vključno z 10 bolnicami (7 %) v skupini, ki je prejemala rukaparib, ki so dosegle popolno remisijo.
Data suggest that rucaparib is a moderate inhibitor of CYP1A2, and a mild inhibitor of CYP2C9, CYP2C19, and CYP3A. 
Podatki kažejo na to, da je rukaparib zmeren zaviralec izoencima CYP1A2 in blag zaviralec izoencimov CYP2C9, CYP2C19 in CYP3A.
60 film-coated tablets. 
60 filmsko obloženih tablet
The adverse reaction frequency is listed by MedDRA System Organ Class (SOC) at the preferred term level. 
Pogostnost neželenih učinkov je predstavljena z uporabo razvrstitve pogostnosti CIOMS III ter so navedeni po organskem sistemu po MedDRA in na ravni prednostnega izraza.
Treatment of BRCA-mutated ovarian cancer after 2 or more chemotherapies The efficacy of rucaparib was investigated in 106 patients in 2 multicentre, single-arm, open-label clinical studies, Study 10 and ARIEL2, in patients with advanced BRCA-mutant epithelial ovarian, fallopian tube or primary peritoneal cancer who had progressed after 2 or more prior chemotherapies (the primary efficacy population). 
Učinkovitost rukapariba so preiskovali pri 106 bolnicah v 2 multicentričnih, odprtih kliničnih študijah z enim krakom, Study 10 in ARIEL2, pri bolnicah z napredovalim epitelijskim rakom jajčnikov, jajcevodov ali primarnim peritonealnim rakom z mutacijo na genu BRCA, pri katerih je bolezen po 2 ali več predhodnih kemoterapijah napredovala (primarna populacija študije učinkovitosti) .
Patients with Renal Impairment 
Bolnice z ledvično okvaro
Most of the primary efficacy population were platinum-sensitive (n=79, 74.5%); the remaining patients were platinum-resistant (n=20, 18.9%) or platinum-refractory (n=7, 6.6%). 
= 79, 74,5 %), preostale bolnice pa so imele raka, ki je bil odporen na platino (n = 20, 18,9 %) ali neodziven na platino (n = 7, 6,6 %).
Leukopeniab, Lymphopeniab, Febrile neutropenia 
Pogosti levkopenijab, limfopenijab, febrilna nevtropenija
In patients with cancer following rucaparib 600 mg taken twice daily, the mean steady-state Cmax was 1940 ng/mL and AUC0-12h was 16900 h⋅ng/mL with Tmax of 1.9 hours. 
Pri bolnicah z rakom je po jemanju rukapariba v odmerku 600 mg dvakrat na dan mediana vrednost Cmax v stanju dinamičnega ravnovesja znašala 1940 ng/m, vrednost AUC 0-12 h pa 16.900 h⋅ng/ml s Tmax 1,9 ure.
Objective response rate (ORR) N 
Stopnja objektivnega odziva (ORR) n % (95-odstotni IZ)
Platinum Sensitive N=79 
N = 79
In vitro, rucaparib is metabolised primarily by CYP2D6, and to a lesser extent by CYP1A2, and CYP3A4. 
In vitro se rukaparib presnavlja primarno prek CYP2D6, v manjšem obsegu pa še prek CYP1A2 in CYP3A4.
Adverse reactions CTCAE Grade 3 or higher occurred in 23% (anaemia), 8% (neutropenia) and 6% (thrombocytopenia) of patients. 
Neželeni učinki stopnje 3 po CTCAE so se pojavili pri 23 % (anemija), 8 % (nevtropenija) in 6 % (trombocitopenija) bolnic.
CYP2C19 substrates 
Substrati CYP2C19
• medicines to treat irregular heartbeats - such as digoxin or quinidine 
• zdravila za zdravljenje nerednega srčnega utripa - npr. digoksin ali kinidin,
Tabulated list of adverse reactions by MedDRA system organ class Adverse reactions 
Preglednica 3: Tabelarični pregled neželenih učinkov v skladu s klasifikacijo MedDRA po organskih sistemih
In an exploratory analysis, a response was noted in 38% (95% CI 23% - 54%) of patients (n=15) on rucaparib compared to 9% (95% CI 1%28%) of patients (n=2) on placebo (2-sided p-value = 0.0055), including 7 (18%) patients in the rucaparib group who achieved a complete remission. 
V eksplorativni analizi te podskupine so odziv ugotovili pri 38 % (95-odstotni IZ 23 % - 54 %) bolnic (n = 15), ki so prejemale rukaparib, v primerjavi z 9 % (95-odstotni IZ 1 % - 28 %) bolnic (n = 2) v skupini, ki je prejemala placebo (dvostranska p-vrednost = 0,0055), vključno s 7 (18 %) bolnicami v skupini, ki so dosegle popolno remisijo.
In vitro, the IC50 of rucaparib against the human ether-à-go-go related gene (hERG) was 22.6 µM, which is approximately 13-fold higher than the Cmax in patients at the recommended dose. 
In vitro je vrednost IC50 rukapariba proti hERG (human ether-à-go-go related gene) znašala 22,6 µM,
Grade ≥ 3 LFT abnormalities. 
PARP-2 in PARP-3.
Oxidation, N-demethylation, N-methylation, glucuronidation, and N-formylation were the major metabolic pathways for rucaparib. 
Glavne presnovne poti za rukaparib so bile oksidacija, N-demetilacija, N-metilacija, glukuronidacija in N-formilacija.
Rubraca can be administered with or without food. 
Zdravilo Rubraca se lahko daje s hrano ali brez nje.
Study 10 population characteristics in 42 patients were: median age 57 years (range 42 to 84), white (83%), ECOG performance status 0 (62%) or 1 (38%), high grade ovarian cancer (100%), 3 or more prior lines of chemotherapy (36%), median time since ovarian cancer diagnosis 43 months [range: 6178], median progression-free interval from the last platinum treatment 8.0 months [range: 6.0 
Značilnosti populacije v študiji Study 10 z 42 bolnicami so bile: mediana starost 57 let (razpon od 42 do 84 let), belke (83 %), stanje zmogljivosti po ECOG 0 (62 %) ali 1 (38 %), rak jajčnikov visoke stopnje (100 %), 3 ali več predhodnih ciklov kemoterapije (36 %), mediani čas od diagnoze raka jajčnikov 43 mesecev (razpon: 6-178), mediani interval brez napredovanja bolezni od zadnjega zdravljenja s platino 8,0 mesecev (razpon: 6,0-116,4).
Yellow, 8 x 16 mm, oval film-coated tablet, debossed with “C3”. 
Rumena, ovalna filmsko obložena tableta velikosti 8 x 16 mm, z oznako "C3"c2.
Based on in vitro data, CYP2D6, and to a lesser extent CYP1A2 and CYP3A4, were able to metabolize rucaparib. 
Na podlagi podatkov in vitro so izoencim CYP2D6, v manjši meri pa tudi izoencima CYP1A2 in CYP3A4, uspešno presnavljali rukaparib.
• The active substance is rucaparib. 
• Učinkovina zdravila Rubraca je rukaparib.
Interrupt treatment if AST/ALT levels do not decline within 2 weeks until Grade ≤ 2, then resume rucaparib at the same or at a reduced dose 
2 tednih ne upadejo na stopnjo ≤ 2, in nato nadaljujte z dajanjem rukapariba v istem ali zmanjšanem odmerku.
ARIEL2 population characteristics in 64 patients were: median age 60 years (range 33 to 80), white(75%), ECOG performance status 0 (61%) or 1 (39%), high grade ovarian cancer (100%), 3 or more prior lines of chemotherapy (78%), median time since ovarian cancer diagnosis 53 months [range: 22-197], median progression-free interval from the last platinum treatment 7.6 months [range: 
Značilnosti populacije v študiji ARIEL2 z 64 bolnicami so bile: mediana starost 60 let (razpon od 33 do 80), belke (75 %), stanje zmogljivosti po ECOG 0 (61 %) ali 1 (39 %), rak jajčnikov visoke stopnje (100 %), 3 ali več predhodnih ciklov kemoterapije (78 %), mediani čas od diagnoze raka jajčnikov 53 mesecev (razpon: 22-197), mediani interval brez napredovanja bolezni od zadnjega zdravljenja s platino 7,6 meseca (razpon: 0,7-26,5).
• For women who are able to become pregnant, a pregnancy test is recommended before starting treatment with Rubraca 
- Pri ženskah v rodni dobi se pred uvedbo zdravljenja z zdravilom Rubraca priporoča test nosečnosti.
Thrombocytopeniab, Neutropeniab, Febrile neutropenia, Leukopeniab 
Pogosti trombocitopenijab, nevtropenijab, febrilna nevtropenija, levkopenijab
• medicines used to treat asthma - such as theophylline 
• zdravila, ki jih uporabljamo za zdravljenje astme - npr. teofilin.
• medicines to treat migraines and headaches - such as dihydroergotamine or ergotamine 
• zdravila za zdravljenje migrene in glavobolov - npr. dihidroergotamin ali ergotamin,
In order to further confirm the safety and efficacy of rucaparib in the treatment of platinum sensitive, relapsed or progressive, BRCA mutated (germline and/ or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, the MAH should submit the results of study CO-338-043 (ARIEL4), a phase 3, multicentre, open-label, randomised study evaluating the efficacy and safety of rucaparib versus chemotherapy for treatment of relapsed ovarian cancer. 
Za nadaljnjo potrditev varnosti in učinkovitosti rukapariba za zdravljenje bolnic z na platino občutljivim, recidivnim ali napredujočim epitelijskim rakom jajčnikov, jajcevodov ali primarnim peritonealnim rakom visoke stopnje, nastalim zaradi mutacij na genu BRCA (germinalnih in/ali somatskih), bo imetnik dovoljenja za promet z zdravilom predložil rezultate študije CO-338-043 (ARIEL4), odprte, multicentrične, randomizirane študije 3.
Rubraca 200 mg film-coated tablets Rubraca 250 mg film-coated tablets Rubraca 300 mg film-coated tablets 
Rubraca 200 mg filmsko obložene tablete Rubraca 250 mg filmsko obložene tablete Rubraca 300 mg filmsko obložene tablete
Effect of P-gp and BCRP inhibitors on rucaparib PK cannot be ruled out. 
Učinkov zaviralcev P-gp in BCRP na farmakokinetiko rukapariba ni mogoče izključiti.
• Rubraca 300 mg film-coated tablets are yellow, oval, film-coated tablets with “C3” marked on one side. 
• Rubraca 300 mg filmsko obložene tablete so rumene, ovalne filmsko obložene tablete z oznako "C3" na eni strani.
• Rubraca 200 mg film-coated tablets are blue, round, film-coated tablets with “C2” marked on one side. 
• Rubraca 200 mg filmsko obložene tablete so modre, okrogle filmsko obložene tablete z oznako "C2" na eni strani.
Rucaparib induced CYP1A2, and down regulated CYP2B6 and CYP3A4 in human hepatocytes at clinically relevant exposures. 
Rukaparib je zaviral CYP1A2, in je pri klinično pomembnih izpostavljenostih v človeških human hepatocitih CYP2B6 in CYP3A4 reguliral navzdol.
• Do not breast-feed during treatment with Rubraca, and for two weeks after taking the last dose. 
Dojenje - Med zdravljenjem z zdravilom Rubraca in še dva tedna po zadnjem odmerku ne smete dojiti.
Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with platinumsensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. 
Zdravilo Rubraca je indicirano kot monoterapija za vzdrževalno zdravljenje odraslih bolnic z na platino občutljivim recidivnim epitelijskim rakom jajčnikov, jajcevodov ali primarnim peritonealnim rakom visoke stopnje, ki se (povsem ali deloma) odziva na kemoterapijo na osnovi platine.
Blood samples for 94% (186/196) of the tBRCA patients were evaluated using a central blood germline BRCA (gBRCA) test. Based on these results, 70% (130/186) of the tBRCA patients had a gBRCA mutation and 30% (56/186) had a somatic BRCA mutation. 
Na podlagi teh rezultatov je 70 % (130/186) bolnic s tBRCA imelo mutacijo gBRCA, 30 % (56/186) pa jih je imelo somatsko mutacijo BRCA.
Moreover, according to its mechanism of action, rucaparib may impact human fertility. 
Glede na mehanizem delovanja lahko rukaparib zmanjša plodnost pri človeku.
(95% CI) 
HR (95-% IZ)
Children unde 18 years of age should not be given Rubraca, This medicine has not beem studied in this age group. 
Otroci, mlajši od 18 let, ne smejo uporabljati zdravila Rubraca.
What you need to know before you take Rubraca Do not take Rubraca: 
Kaj morate vedeti, preden boste vzeli zdravilo Rubraca
No starting dose adjustment is required in patients with mild or moderate renal impairment (see section 5.2). 
Pri bolnicah z blago ali zmerno okvaro ledvic prilagoditev začetnega odmerka ni potrebna (glejte poglavje 5.2).
Patients with mild renal impairment (N=149; CLcr between 60 and 89 mL/min, as estimated by the Cockcroft-Gault method) and those with moderate renal impairment (N=76; CLcr between 30 and 59 mL/min) showed approximately 15% and 33% higher steady-state AUC, respectively, compared to patients with normal renal function (N=147; CLcr greater than or equal to 90 mL/min). 
Populacijska farmakokinetična analiza je bila opravljena z namenom ocene učinka okvare ledvic na očistek rukapariba pri bolnicah, ki so prejemale rukaparib v odmerku 600 mg dvakrat na dan. Bolnice z blago okvaro ledvic (N = 149; CLcr med 60 in 89 ml/min, ocenjeno z Cockcroft-Gaultovo metodo) in bolnice z zmerno okvaro ledvic (N = 76; CLcr med 30 in 59 ml/min) so imele približno 15 % in 33% višjo vrednost AUC v stanju dinamičnega ravnovesja v primerjavi z bolnicami z normalnim delovanjem ledvic (N = 147; CLcr večji ali enak 90 ml/min).
Patients could not have received prior rucaparib or other PARP inhibitor therapy. 
Bolnice predhodno niso smele prejemati rukapariba ali drugega zdravljenja z zaviralcem PARP.
What Rubraca is used for 
Za kaj uporabljamo zdravilo Rubraca
Enzymes responsible for rucaparib metabolism have not been identified. 
Encimov, ki so odgovorni za presnavljanje rukapariba, še niso prepoznali.
In vitro, rucaparib is a potent inhibitor of MATE1 and MATE2-K, a moderate inhibitor of OCT1, and a weak inhibitor of OCT2. 
In vitro je rukaparib je močan zaviralec MATE1 in MATE2-K, zmeren zaviralec OCT1 in šibek zaviralec OCT2.
No cardiac effects were observed with oral dosing of rucaparib in repeat-dose toxicology studies at a rucaparib Cmax comparable to that observed in patients. 
V študijah toksičnosti s ponavljajočimi peroralnimi odmerki rukapariba niso opazili učinkov na srce pri vrednosti Cmax rukapariba, primerljivi z vrednostjo pri bolnicah.
Rucaparib is a potent inhibitor of MATE1 and MATE2-K, a moderate inhibitor of OCT1, and a weak inhibitor of OCT2. 
Rukaparib je močan zaviralec MATE1 in MATE2-K, zmeren zaviralec OCT1 in šibek zaviralec OCT2.
Myelodysplastic syndrome / Acute myeloid leukaemia 
Mielodisplastični sindrom/akutna mieloična levkemija
In the tBRCA population, 31% of patients (40/130) in the rucaparib group and 35% of patients (23/66) in the placebo group had measurable disease at baseline. 
V populaciji tBRCA je 31 % bolnic (40/130) v skupini, ki je prejemala rukaparib, in 35 % bolnic
Rash maculo-papular, Palmarplantar erythrodysaesthesia syndrome, Erythema 
Pogosti makulopapulozni izpuščaj, sindrom palmarno-plantarne eritrodisestezije, eritem
• Rubraca 250 mg film-coated tablets are white, diamond-shaped, film-coated tablets with “C25” marked on one side. 
• Rubraca 250 mg filmsko obložene tablete so bele filmsko obložene tablete v obliki romba z oznako "C25" na eni strani.
There is no specific treatment in the event of Rubraca overdose, and symptoms of overdose are not established. 
Specifičnega zdravljenja za preveliko odmerjanje zdravila Rubraca ni.
In patients with moderate renal impairment (CLcr of 30-59 mL/min), frequencies of some adverse reactions increased: Grade 3 or 4 anaemia (31%), Grade 3 or 4 thrombocytopenia (12%), and Grade 3 fatigue/asthenia (15%) were higher than in patients with mild renal impairment (CLcr > 59-80 mL/min) or normal renal function (CLcr > 80 mL/min) (21%, 5%, and 8%). 
Pri bolnicah z zmerno ledvično okvaro (vrednost CLcr 30-59 ml/min) so bile pogostnosti nekaterih neželenih učinkov večje: anemija 3. ali 4. stopnje (31 %), trombocitopenija 3. ali 4. stopnje (12 %) in utrujenost/astenija 3. stopnje (15 %) so bile pogostejše kot pri bolnicah z blago ledvično okvaro
No starting dose adjustment is required in patients with mild hepatic impairment (see section 5.2). 
Pri bolnicah z blago okvaro jeter prilagoditev začetnega odmerka ni potrebna (glejte poglavje 5.2).
Rucaparib increased midazolam Cmax by 1.13 fold (90% CI: 0.95 to 1.36) and AUCinf by 1.38 fold (90% CI: 1.13 to 1.69). 
Rukaparib je povišal Cmax midazolama za 1,13-krat (90-odstotni IZ: 0,95 do 1,36,) AUCinf pa za 1,38krat (90-odstotni IZ: 1,13 do 1,69).
Rucaparib increased S-warfarin Cmax by 1.05 fold (90% CI: 0.99 to 1.12) and AUC0-96h by 1.49 fold (90% CI: 1.40 to 1.58), respectively. 
Rukaparib je povišal Cmax S-varfarina za 1,05-krat (90-odstotni IZ: 0,99 do 1,12), AUC0-96 h pa za 1,49-krat (90-odstotni IZ: 1,40 do 1,58).
Rucaparib increased omeprazole Cmax by 1.09 fold (90% CI: 0.93 to 1.27) and AUCinf by 1.55 fold (90% CI: 1.32 to 1.83). 
Rukaparib je povišal Cmax omeprazola za 1,09-krat (90-odstotni IZ: 0,93 do 1,27), AUCinf pa za 1,55krat (90-odstotni IZ: 1,32 do 1,83).
Blue, 11 mm, round film-coated tablet, debossed with “C2”. 
Modra, okrogla filmsko obložena tableta premera 11 mm z oznako "C2".
There are no animal studies on the excretion of rucaparib in breast milk. 
Študij na živalih o izločanju rukapariba v mleko ni. Ni znano, ali se rukaparib in/ali njegovi presnovki izločajo v materino mleko.
Thus, the risk for clinically significant QTcF increase from baseline (i.e. > 20 msec) is low. 
Zato je tveganje za klinično pomembno podaljšanje intervala QTcF od izhodišča (t.j.
Dysgeusia, Dizziness 
Občasni disgevzija, omotica
No dose adjustment is recommended for co-administered medicinal products that are P-gp substrates. 
Za sočasna zdravila, ki so substrati P-gp, prilagajanje odmerka ni priporočeno.
Median overall survival - months (95% CI) 
Mediano celokupno preživetje meseci (95-% IZ) Cenzorirano N (%)
No formal studies of rucaparib in patients with renal impairment have been conducted. 
Formalnih študij z rukaparibom pri bolnicah z motnjami v delovanju ledvic niso izvedli.
Women of childbearing potential should be advised to avoid becoming pregnant while receiving rucaparib. 
Bolnicam v rodni dobi je treba odsvetovati nosečnost v obdobju, ko prejemajo rukaparib.
Hepatobiliary disorders Very common 
Zelo pogosti anemijab
Grade 3 without other signs of liver dysfunction Monitor LFTs weekly until resolution to Grade ≤ 2 
Stopnja 3 brez drugih znakov nepravilnega delovanja jeter
Missed doses If a dose is missed, the patient should resume taking Rubraca with the next scheduled dose. 
Če bolnica izpusti odmerek zdravila Rubraca, mora vzeti naslednji odmerek ob običajnem času.
White, 11 x 15 mm, diamond-shaped film-coated tablet, debossed with “C25”. 
Bela filmsko obložena tableta v obliki romba velikosti 11 x 15 mm z oznako "C25".
Hepatic impairment No formal studies of rucaparib in patients with hepatic impairment have been conducted. 
Formalnih študij z rukaparibom pri bolnicah z motnjami v delovanju jeter niso izvedli.
Fertility studies have not been conducted with rucaparib. 
Študij plodnosti z rukaparibom niso opravili.
• Rubraca is not recommended during pregnancy. 
- Uporaba zdravila Rubraca med nosečnostjo ni priporočljiva.
In the ITT population, 38% of patients (141/375) in the rucaparib group and 35% of patients (66/189) in the placebo group had measurable disease at baseline. 
V populaciji ITT je 38 % bolnic (141/375) v skupini, ki je prejemala rukaparib, in 35 % bolnic
Description of selected adverse reactions 
Opis izbranih neželenih učinkov Hematološka toksičnost
vomiting, anaemia, abdominal pain, dysgeusia, ALT elevations, AST elevations, decreased appetite, diarrhoea, thrombocytopenia and creatinine elevations. 
Neželeni učinki, ki so se pojavili pri ≥ 20 % bolnic, ki so prejemale rukaparib, so bili navzea, utrujenost/astenija, bruhanje, anemija, bolečine v trebuhu, disgevzija, zvišanje ravni ALT, zvišanje ravni AST, zmanjšanje teka, driska, trombocitopenija in zvišanje ravni kreatinina.
Always take this medicine exactly as your doctor, pharmacist or nurse has told you. 
Pri jemanju tega zdravila natančno upoštevajte navodila zdravnika, farmacevta ali medicinske sestre.
Rubraca 250 mg film-coated tablets: Each film-coated tablet contains rucaparib camsylate corresponding to 250 mg of rucaparib. 
Rubraca 250 mg filmsko obložene tablete: ena filmsko obložena tableta vsebuje rukaparibijev kamsilat v količini 250 mg rukapariba.
Population PK analysis suggested that concomitant use of PPIs is unlikely to have clinically meaningful impact on rucaparib PK. A firm conclusion cannot be made regarding the effect of co-administration of rucaparib and PPIs because dose level and time of administration have not been documented in detail for the PPIs. 
Dokončne ugotovitve o učinku sočasnega dajanja rukapariba in zaviralcev protonske črpalke ni mogoče podati, saj ravni odmerka in časa dajanja zaviralcev protonske črpalke niso podrobno dokumentirali.
There is no requirement for BRCA testing prior to using Rubraca for the maintenance treatment of adult patients with relapsed high-grade epithelial ovarian cancer (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) who are in a complete or partial response to platinum-based chemotherapy. 
Pred uporabo zdravila Rubraca za vzdrževalno zdravljenje odraslih bolnic z recidivnim epitelijskim rakom jajčnikov (EOC - epithelial ovarian cancer), jajcevodov (FTC - fallopian tube cancer) ali primarnim peritonealnim rakom (PPC - primary peritoneal cancer) visoke stopnje, ki se povsem ali deloma odzivajo na kemoterapijo na osnovi platine, ni potrebno testiranje za mutacijo BRCA.
Rubraca 300 mg film-coated tablets: Each film-coated tablet contains rucaparib camsylate corresponding to 300 mg of rucaparib. 
Rubraca 300 mg filmsko obložene tablete: ena filmsko obložena tableta vsebuje rukaparibijev kamsilat v količini 300 mg rukapariba.
Prior bevacizumab therapy was reported for 22% of patients who received rucaparib and 23% of patients who received placebo. 
in pri 23 % bolnic, ki so prejemale placebo, so poročali o predhodnem zdravljenju z bevacizumabom.
Management 
Uravnavanje
• If you get any side effects, talk to your doctor, pharmacist or nurse. 
• Če opazite katerega koli izmed neželenih učinkov, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Nausea, Vomiting, Diarrhoea, Dyspepsia, Abdominal pain 
Zelo pogosti navzea, bruhanje, driska, dispepsija, bolečine v trebuhu
Photosensitivity reaction, Rash, Rash maculo-papular, Palmarplantar erythrodysaesthesia syndrome 
izpuščaj, makulopapulozni izpuščaj, sindrom palmarnoplantarne eritrodisestezije
Rubraca 200 mg film-coated tablets: Each film-coated tablet contains rucaparib camsylate corresponding to 200 mg of rucaparib. 
Rubraca 200 mg filmsko obložene tablete: ena filmsko obložena tableta vsebuje rukaparibijev kamsilat v količini, ki ustreza 200 mg rukapariba.
The clearance ranged from 13.9 to 18.4 L/hour, following a single intravenous dose of rucaparib 12 mg to 40 mg. 
MOčistek je po enkratnem intravenskem odmerku rukapariba od 12 mg do 40 mg znašal od 13,9 do 18,4 l/uro.
Dysgeusia, Dizziness, 
Zelo pogosti disgevzija, omotica
- Rubraca 300 mg film-coated tablets Polyvinyl alcohol (E1203), titanium dioxide (E171), macrogol 4000 (E1521), talc (E553b), and iron oxide yellow (E172). 
Rubraca 300 mg filmsko obložene tablete polivinilalkohol (E1203), titanov dioksid (E171), makrogol 4000 (E1521), smukec (E553b) in rumeni železov oksid (E172).
Tablet coating Polyvinyl alcohol (E1203) Titanium dioxide (E171) Macrogol 4000 (E1521) 
Obloga tablete polivinilalkohol (E1203) titanov dioksid (E171) makrogol 4000 (E1521) smukec (E553b)
- Rubraca 250 mg film-coated tablets Polyvinyl alcohol (E1203), titanium dioxide (E171), macrogol 4000 (E1521), and talc (E553b) 
Rubraca 250 mg filmsko obložene tablete polivinilalkohol (E1203), titanov dioksid (E171), makrogol 4000 (E1521) in smukec (E553b).
Rubraca 300 mg film-coated tablets rucaparib This medicine is subject to additional monitoring. 
Rubraca 200 mg filmsko obložene tablete Rubraca 250 mg filmsko obložene tablete Rubraca 300 mg filmsko obložene tablete rukaparib Za to zdravilo se izvaja dodatno spremljanje varnosti.
Anaemiab, Thrombocytopeniab, Neutropeniab 
Zelo pogosti anemijab, trombocitopenijab, nevtropenijab,
How to take Rubraca 
Kako jemati zdravilo Rubraca
You may get sunburn more easily during treatment with Rubraca. 
Med zdravljenjem z zdravilom Rubraca lahko hitreje dobite sončne opekline.